Table 1.

Clinical characteristics of 41 patients with head and neck squamous cell carcinoma (received concurrent cetuximab and nivolumab) profiled with peripheral blood mononuclear cells immunosequencing

	Overall (N=41)
Age on study
Mean (SD)	61.6 (11.3)
Median (min, max)	64.0 (24.0, 78.0)
Gender
Female	8 (19.5%)
Male	33 (80.5%)
Race
Asian	1 (2.4%)
Black or African American	2 (4.9%)
White	37 (90.2%)
Unknown	1 (2.4%)
Primary site
Hypopharynx	1 (2.4%)
Larynx	3 (7.3%)
Oral cavity	13 (31.7%)
Oropharynx	23 (56.1%)
Unknown primary	1 (2.4%)
p16 status
Negative	18 (43.9%)
Positive	23 (56.1%)
Smoking history
Current smoker	4 (9.8%)
Previous smoker	21 (51.2%)
Never smoked	16 (39.0%)
ECOG PS
0	14 (34.1%)
1	25 (61.0%)
2	2 (4.9%)
Prior immunotherapy
No	24 (58.5%)
Yes	17 (41.5%)
Best response
Complete response	3 (7.3%)
Partial response	6 (14.6%)
Stable disease	20 (48.8%)
Progressive disease	10 (24.4%)
Not assessed	2 (4.9%)
Survival status
Alive	14 (34.1%)
Death	27 (65.9%)

ECOG PS, Eastern Cooperative Oncology Group Performance Status.